<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04409886</url>
  </required_header>
  <id_info>
    <org_study_id>120-20-ASF</org_study_id>
    <nct_id>NCT04409886</nct_id>
  </id_info>
  <brief_title>Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients</brief_title>
  <acronym>HBOT</acronym>
  <official_title>The Application of Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients - Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimonides Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective randomized controlled, double blind clinical trial performed on&#xD;
      laboratory confirmed COVID-19 infection admitted patients in the Shamir Medical Center. The&#xD;
      trial will include 30 patients who will undergo either hyperbaric oxygen therapy (HBOT) or&#xD;
      Normobaric oxygen therapy (NBOT), randomized on a 2:1 ratio, within 4 days in addition to the&#xD;
      standard treatment including oxygen, drugs, steroids, bronchodilators, antibiotics and&#xD;
      others.&#xD;
&#xD;
      The evaluation procedure includes symptom monitoring, room air saturation, vital signs&#xD;
      monitoring, pulmonary function and blood tests at baseline, one day and one week after the&#xD;
      last session. In addition, one hour prior to and post session saturation and vitals will be&#xD;
      monitored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective randomized controlled, double blind clinical trial performed on&#xD;
      laboratory confirmed COVID-19 infection admitted patients at MMC. The trial will include 30&#xD;
      patients who will undergo either HBOT or NBOT, randomized on a 2:1 ratio, within 4 days in&#xD;
      addition to the standard treatment including oxygen, drugs, steroids, bronchodilators,&#xD;
      antibiotics and others.&#xD;
&#xD;
      Sessions will be provided in an MMC monoplace HBO chamber (RestorixHealth). Since all&#xD;
      patients demand oxygen supply at room air, the control group is an active arm receiving 100%&#xD;
      oxygen. For HBOT, each session will include breathing 100% oxygen at 2.2 absolute atmospheres&#xD;
      (ATA) for 60 minutes. Compression and decompression will occur at 1 meter/minute rate. For&#xD;
      NBOT, each session will include breathing 100% oxygen at 1.0 absolute atmospheres (ATA) for&#xD;
      60 minutes. In order to blind the patient, the first 5 minutes will include compression for&#xD;
      1.1 ATA and then decompression to 1.0 within the next 5 minutes.&#xD;
&#xD;
      During the sessions, the symptoms and vitals will be monitored. The evaluation procedure will&#xD;
      include symptom monitoring, room air saturation, vital signs monitoring, pulmonary function&#xD;
      and blood tests at baseline, one day and one week after the last session. In addition, one&#xD;
      hour prior to and post session saturation and vitals will be monitored. Sessions and&#xD;
      evaluations procedures will occur as the following:&#xD;
&#xD;
      Protocol Day 1&#xD;
&#xD;
        1. Baseline evaluation: blood test including: arterial blood gases, 2 CBC tubes, 2 Gel&#xD;
           tubes (10-15 cc total), vitals (temperature, blood pressure, heart rate, room air&#xD;
           saturation), symptoms questionnaire, pulmonary function test.&#xD;
&#xD;
        2. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour prior to&#xD;
           session&#xD;
&#xD;
        3. One-hour session NBO/HBO&#xD;
&#xD;
        4. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour after the&#xD;
           session.&#xD;
&#xD;
        5. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour before the&#xD;
           2nd session.&#xD;
&#xD;
        6. One-hour session NBO/HBO (8 hours following the first session)&#xD;
&#xD;
        7. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour after the&#xD;
           session.&#xD;
&#xD;
        8. Daily oxygen supply dose monitoring. Protocol Day 2-4&#xD;
&#xD;
      1. Daily symptoms questionnaire 2. Vitals (temperature, blood pressure, heartrate, room air&#xD;
      saturation) one hour prior to session One-hour session NBO/HBO 3. Vitals (temperature, blood&#xD;
      pressure, heartrate, room air saturation) one hour after the session.&#xD;
&#xD;
      4. Vitals (temperature, blood pressure, heartrate, room air saturation) one hour before the&#xD;
      2nd session.&#xD;
&#xD;
      5. One-hour session NBO/HBO (8 hours following the first session) 6. Vitals (temperature,&#xD;
      blood pressure, heartrate, room air saturation) one hour after the session.&#xD;
&#xD;
      7. Daily oxygen supply dose monitoring. Follow up Protocol&#xD;
&#xD;
        1. Repeat evaluations one day after the last session and one week after the last session:&#xD;
&#xD;
             -  Blood test including: arterial blood gases, 2 CBC tubes, 2 Gel tubes (10-15 cc&#xD;
                total)&#xD;
&#xD;
             -  Vitals (temperature, blood pressure, heart rate, room air saturation)&#xD;
&#xD;
             -  Symptoms questionnaire&#xD;
&#xD;
             -  Pulmonary function test.&#xD;
&#xD;
        2. Oropharyngeal swab for SARS-CoV-2 RT-PCR every 3 days for 1 week&#xD;
&#xD;
        3. Clinical monitoring for 30 days&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study is part of a larger national study. Only 1 patient was enrolled at Maimonides;&#xD;
    Medical Center. The study was ended by the sponsor because the PI left; funding ended; , and no&#xD;
    time, or personnel to do the study&#xD;
  </why_stopped>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Actual">January 31, 2021</completion_date>
  <primary_completion_date type="Actual">January 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygenation Index</measure>
    <time_frame>one day after the last session</time_frame>
    <description>PaO2/FiO2 (Oxygenation Index)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>COVID, Coronavirus</condition>
  <arm_group>
    <arm_group_label>HBOT (Hyperbaric Oxygen Therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hyperbaric Oxygen Therapy</intervention_name>
    <description>Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)</description>
    <arm_group_label>HBOT (Hyperbaric Oxygen Therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Within 7 days of patient's need of oxygen supply&#xD;
&#xD;
          -  Positive SARS-CoV-2 RT-PCR&#xD;
&#xD;
          -  At least one risk factor for bad prognosis of COVID-19: hypertension, diabetes&#xD;
             mellitus, ischemic heart disease, smoking, age&gt;50, etc.&#xD;
&#xD;
          -  Respiratory insufficiency: Room Air SpO2 &lt;94% or PaO2/FiO2&lt;300mmHg&#xD;
&#xD;
          -  Age&gt;18&#xD;
&#xD;
          -  Ability to sign an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Negative SARS-CoV-2 RT-PCR&#xD;
&#xD;
          -  HBOT contraindication: pneumothorax, pneumomediastinum, claustrophobia, ear/sinus&#xD;
             disease which aren't allowed in HBOT, known chronic pulmonary disease: severe&#xD;
             emphysema or known pulmonary bullae.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to sign an informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ory Wiesel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2020</study_first_posted>
  <results_first_submitted>May 25, 2021</results_first_submitted>
  <results_first_submitted_qc>June 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2021</results_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will not be shared</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT04409886/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HBOT (Hyperbaric Oxygen Therapy)</title>
          <description>Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)&#xD;
Hyperbaric Oxygen Therapy: Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HBOT (Hyperbaric Oxygen Therapy)</title>
          <description>Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)&#xD;
Hyperbaric Oxygen Therapy: Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Oxygenation Index</title>
        <description>PaO2/FiO2 (Oxygenation Index)</description>
        <time_frame>one day after the last session</time_frame>
        <population>PI left institution and the study was terminated with only 1 participant enrolled. No data available to report</population>
        <group_list>
          <group group_id="O1">
            <title>HBOT (Hyperbaric Oxygen Therapy)</title>
            <description>Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)&#xD;
Hyperbaric Oxygen Therapy: Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygenation Index</title>
          <description>PaO2/FiO2 (Oxygenation Index)</description>
          <population>PI left institution and the study was terminated with only 1 participant enrolled. No data available to report</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>Adverse events includes adverse events that result in any of the following outcomes: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions</desc>
      <group_list>
        <group group_id="E1">
          <title>HBOT (Hyperbaric Oxygen Therapy)</title>
          <description>Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)&#xD;
Hyperbaric Oxygen Therapy: Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gene Sobol</name_or_title>
      <organization>Maimonides Medical Center</organization>
      <phone>718-283-6000</phone>
      <email>gsobol@maimonidesmed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

